Clinical Features of Rheumatoid Arthritis in a Sub-Saharan African Population: A 308 Study Cases in Senegal

Souhaibou Ndongo, MD, Abdoulaye Pouye, MD, Emeric Azankpan, MD, Mourtalla Mamadou Ka¹, MD, and Thérèse Moreira Diop, MD

Department of Internal Medicine, Aristide Le Dantec Teaching Hospital
University of Dakar, Dakar, Senegal
¹Department of Internal Medicine, University of Thies, Thies, Senegal

ABSTRACT

Background: Rheumatoid arthritis, formerly rare in sub-Saharan Africa, is becoming increasingly reported. The objective study determines the epidemiological, clinical and biological features of rheumatoid arthritis at diagnosis.

Methods: A cross-sectional study conducted at the Rheumatology outpatient department of Aristide Le Dantec Teaching Hospital of Dakar in Senegal.

Results: Three hundred eight patients with rheumatoid arthritis according, to American College of Rheumatology 1987 criteria, were included: 273 women and 35 men (ratio of 7.8). Median age was 41 years (Q1: 31; Q3: 53 years); predominant age group was 30-40 years. Ninety-three percent resided in urban areas and 7% in rural areas. Family history of chronic inflammatory arthritis was reported by 35.1% of patients. Thirty-nine percent of patients initially consulted a traditional healer. On admission, the median Disease Activity Score 28 was 6.5 (Q1: 5.5; Q3: 7.3). Rheumatoid arthritis was very active in 81.1% and a positive factor in 84% of patients. Cyclic citrullinated peptide antibodies assessed in 116 patients; 95 reported positive (81.9%). Of 169 patients, at least one extra-articular manifestation was presented; the most common, anemia and sicca syndrome.

Conclusion: Rheumatoid arthritis was characterized by an important delay in diagnosis, a polyarticular presentation, and a high positivity of immunological markers. Extra-articular manifestations included mainly anemia and sicca syndrome. Early management and a better understanding of rheumatoid arthritis in sub-Saharan Africa are required.

Keywords
Rheumatoid arthritis, Sub-Saharan African, Senegal
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease of connective tissue, affecting mostly the synovial joints. It can be associated with disabling joint destruction and extra-articular manifestations that can affect survival rates. Rheumatoid arthritis (RA) affects all populations, although its prevalence varies from one region to another: it is estimated at approximately 0.5 to 1% in developed countries\(^1\). Formerly speculated as rare in sub-Saharan Africa region due to the lack of specialist, thus recently, becoming increasingly described\(^2,3\). Though, RA was previously presumed relatively benign in sub-Saharan Africa\(^2\); however, recent data suggest a greater severity. In fact, in a previous study on 100 patients, it showed RA activity very high at the time of diagnosis in Senegal\(^4\).

The objective of this study was to determine the epidemiological, clinical, biological and immunological features of RA at diagnosis in a sub-Saharan African population.

PATIENTS AND METHODS
This cross-sectional cohort study was conducted at the rheumatology outpatient department of the Medical Clinic 1 at the Aristide Le Dantec Teaching Hospital of Dakar in Senegal from October 2005 to December 2012, in accordance with the ethical principles of the Declaration of Helsinki. The Ethics Committee of the Medical School of Dakar approved the study.

All patients with RA according to the criteria from the American College of Rheumatology (modified in 1987) were included in the study\(^5\). For all patients, the following data were collected: Demographic data (age, gender, place of residence), clinical data (diagnostic delay, articular index, synovial index, number of awakenings at night, duration of morning stiffness, and extra-articular signs) and biological parameters (blood count, erythrocyte sedimentation rate, C reactive protein, rheumatoid factors, cyclic citrullinated peptide antibodies). Disease activity at diagnosis was assessed with the Disease Activity Score 28 (DAS28, Web Version 4.05) test.

The lab norms for variables was: ESR < 15 mm in first hour; CRP < 6 mg/l; hemoglobin [12-16 g/dl]; RF < 8 IU; anti-CCP < 25 IU.

Quantitative variables were reported as median (1st quartile, 3rd quartile) because of their non-normal distribution, and reported as a percentage for each modality of the variable.

RESULTS
A total of 308 patients with RA were included in the study. The main baseline characteristics of the patients are summarized in Table 1. The population included 273 women and 35 men, for a sex ratio of 7.8 (W/M). The median age was 41 years (Q1: 31; Q3: 53 years). The predominant age group was 30-40 years, followed by 40-50 years (Fig. 1).

Ninety-three percent of the study population resided in urban areas, and 7% resided in rural areas. A family history of chronic inflammatory arthritis was reported by 35.1% of patients. Thirty-nine percent of patients had initially consulted a traditional healer. On admission, the median DAS28 was 6.5 (Q1: 5.5; Q3: 7.3). RA was very active in 81.1% of patients, with a DAS28 > 5.1. The median number of painful joints was 27, with a median duration of morning stiffness of two hours. Hand deformities were generally symmetrical (Fig. 2).

Rheumatoid factors were positive in 84% of patients. Cyclic citrullinated peptide antibodies were assessed in 116 patients and were positive in 95 of them (81.9%). The extra-articular manifestations reported are summarized in Table 2. A total of 169 patients presented at least one extra-

### TABLE 1.
Main characteristics of the RA study population at diagnosis.

| Variables at the Time of Diagnosis | Percentage (%) or Median (Q1;Q3) |
|-----------------------------------|----------------------------------|
| Evolution of symptoms before diagnosis (in months) | 46 (24;90) |
| Number of painful articulations | 27 (16;30) |
| Number of synovitis | 3 (1;10) |
| Duration of morning stiffness (in hours) | 2 (1;3) |
| Positive CRP (> 6 mg/l) | 90.2% |
| High ESR (>15 mm in first hour) | 85.9% |
| Positive rheumatoid factors (> 8 IU) | 84.0% |
| Positive anti-cyclic citrullinated peptide antibodies (>25 IU) | 95/116 (81.9%) |
| DAS28 | 6.5 (5.5;7.3) |
| RA in remission\(^a\) | 0.7% |
| Mild activity\(^b\) | 1.3% |
| Moderate activity\(^c\) | 16.9% |
| Very active\(^d\) | 81.1% |

\(\text{DAS: Disease Activity Score with 28 joints count}
\)

\(^a\)DAS \leq 2.6
\(^b\)2.6 < \text{DAS} \leq 3.2
\(^c\)3.2 < \text{DAS} \leq 5.1
\(^d\)5.1 < \text{DAS}\)
articular manifestation, the most common being anemia and sicca syndrome.

Tables 3 and 4 show the effect of sex and age at the beginning of the symptomatology. Women were significantly more affected in less than 60 years.

**DISCUSSION**

Through the analysis of 308 cases, this study enables to assess the epidemiological, clinical, biochemical and immunological features of RA in a sub-Saharan African population, where there has been an insurrection in RA therapy in the past few years.

Rheumatoid arthritis (RA) remains poorly acknowledged by the medical staff in Senegal, which results in a significant delay in diagnosis. The median duration of

**FIGURE 1.**

Age distribution of the study population (by 10-year ranges).

**FIGURE 2.**

Hand deformities distribution at time of diagnosis. “Overall” represents both left and right hand deformities.

| Variables                          | N (%)     |
|-----------------------------------|-----------|
| Anemia                            | 102/308 (33.1%) |
| Sicca syndrome                    | 90/308 (29.2%) |
| Interstitial pneumonia            | 6/308 (2.0%) |
| Rheumatoid nodules                | 4/308 (1.3%) |
| Adenopathies                      | 4/308 (1.3%) |
| Fever                             | 2/308 (0.7%) |

**TABLE 2.**

Extra-articular manifestations.

| Number of Extra-Articular Manifestations per Patient |
|------------------------------------------------------|
| 0                                                   | 139/308 (45.1%) |
| 1                                                   | 136/308 (44.2%) |
| 2                                                   | 27/308 (8.8%) |
| 3                                                   | 6/308 (1.9%) |
| At least 1 manifestation                            | 169/308 (54.9%) |
**TABLE 3.**

Effect of the age at the beginning of symptomatology.

|                        | Less than 60 years | 60 years or more | p-value |
|------------------------|--------------------|------------------|---------|
| **Sex**                | N = 270 (91%)      | N = 26 (9%)      |         |
| **Women**              | 244/270 (90.4%)    | 18/26 (69.2%)    | p=0.005 |
| **Men**                | 26/270 (9.6%)      | 8/26 (30.8%)     |         |
| **Urban**              | 207/260 (79.6%)    | 15/25 (60.0%)    | p=0.02  |
| **Rural**              | 53/260 (20.4%)     | 10/25 (40.0%)    |         |
| **Disease Activity Score 28** | 6.6 (5.5; 7.3) | 6.0 (5.3; 6.5) | p=0.10  |
| **Min; Max**           | 1.4; 9.7           | 2.7; 7.3         |         |
| **Duration of Evolution of Symptomatology (Month)** | 47 (24; 92) | 37 (28; 58) | p=0.45  |
| **Median (Q1; Q3)**   | 4; 1382            | 9; 141           |         |
| **Positive Rheumatoid Factors (> 8 IU)** | 87%              | 60%              | -       |
| **Positive anti CCP Antibodies (> 25 IU)** | 83%              | 67%              | -       |
| **Extra-Articular Signs** | 120/270 (44.4%) | 10/26 (38.5%) | p=0.56  |
| **No sign**            | 150/270 (55.6%)   | 16/26 (61.5%)    |
| **At least a sign**    |                    |                  |

**TABLE 4.**

Difference of the symptomatology men/women at the beginning of symptomatology.

|                        | Women N = 273 (89%) | Men N = 35 (11%) | p-value |
|------------------------|---------------------|------------------|---------|
| **Age (years)**        |                     |                  |         |
| **Median (Q1; Q3)**    | 41 (30; 52)         | 42 (34; 68)      | p=0.17  |
| **Min; Max**           | 16; 81              | 17; 80           |         |
| **Urban**              | 78.9%               | 72.7%            | p=0.42  |
| **Rural**              | 21.1%               | 27.3%            |         |
| **Disease Activity Score 28** | 6.5 (5.5; 7.3) | 6.5 (5.1; 7.1) | p=0.40  |
| **Median (Q1; Q3)**    | 1; 4.97             | 2.7; 7.7         |         |
| **Min; Max**           |                     |                  |         |
| **Duration of Evolution of Symptomatology (Month)** | 46 (25; 90) | 44 (22; 84) | p=0.48  |
| **Median (Q1; Q3)**    | 1; 382              | 5; 260           |         |
| **Positive Rheumatoid Factors (> 8 IU)** | 32 (12; 160) | 32 (12; 64) | p=0.72  |
| **Median (Q1; Q3)**    | 6; 1024             | 6; 512           |         |
| **Min; Max**           |                     |                  |         |
| **Positive Anti CCP antibodies (> 25 IU)** | 100 (13; 340) | 160 (10; 340) | p=0.88  |
| **Median (Q1; Q3)**    | 0; 340              | 2; 340           |         |
| **Min; Max**           |                     |                  |         |
| **Extra-Articular Signs** | 122/273 (44.7%) | 17/35 (48.6%) | p=0.66  |
| **Aucun signe**        | 151/273 (55.3%)     | 18/35 (51.4%)    |
| **Au moins un signe**  | 0; 28               | 0; 28            |         |

Symptoms before diagnosis was 46 months in this study, which is a long time, but it is lower than the 54-month period previously reported in Senegal[46]. This significant delay in diagnosis was described in other African studies[2,6]. In Western studies, the delay in diagnosis is lower. In France it was estimated at 6 months[73]. Therefore, efforts should be made to further reduce diagnostic delay periods. The increasingly common use of the ACR/EULAR 2010 criteria[96] should be allowed for an earlier diagnosis of RA.

A clear female predominance was found in our series. This female predominance in RA has been widely
reported in both African and Western studies, although it tends to decline with age. The role of hormonal factors is incriminated in this constatation[11].

The median age was 41 years (Q1: 31; Q3: 53). This result is comparable to data from other African studies[26,28], and is well below the age of 55 years reported in Western countries[27,29], and of 54 years reported in the African-American population[10]. We were unable to characterize the family history of chronic inflammatory arthritis, which is under genetic control during RA, and other systemic autoimmune diseases[11]. On admission, RA was active in 81.1% of patients, according to the DAS28. This could be due to the significant delay in diagnosis or an inappropriate initial therapy, especially because many patients first go to traditional healers[9]. Because of the limited number of physicians, particularly those who specialize in rheumatic diseases, access to traditional healers is easier for our patients. Moreover, the high number of patients with both positive rheumatoid factors and positive cyclic citrullinated peptide antibodies could help explained the severity of RA in our patients. Indeed, the presence of rheumatoid factors and cyclic citrullinated peptide antibodies is associated with a poor prognosis[12-13]. In addition, extra-articular manifestations, which are also considered poor prognostic factors, were detected in more than half of the patients. Among African-Americans, 38% of patients present extra-articular manifestations[1]. Our results contrast with previous data, which suggested that extra-articular manifestations were rare in the sub-Saharan African population[21,24]. Although, the interpretation of hospital studies should be done with caution as it includes a limited number of patients. However, rheumatoid nodules, which indicate severe RA, were found in only 1.3% of our patients, despite the high seropositivity for rheumatoid factors (84%) and cyclic citrullinated peptide antibodies (81.9%).

The present study presents some limitations. First, the recruitment of patients in a hospital setting could constitute a selection bias. A population-based study would be more appropriate, but the limited number of rheumatologists in Senegal makes this type of study difficult to perform. However, due to the number of RA cases included in this study (308 patients), this is one of the largest RA series described in sub-Saharan Africa. Second, a radiological assessment of lesions would have provided additional information for determining the rate of RA severity in Senegal. Nevertheless, in a previous study, we showed that radiological lesions are noted in 56% of patients at diagnosis, with a modified Sharp score of 21.8 ± 47.7[4].

CONCLUSIONS
In a Senegalese hospital setting, RA is characterized by an important delay in diagnosis, a polyarticular presentation, and a high number of extra-articular manifestations plus a high positivity of immunological markers. RA extra-articular manifestations include mainly anemia and sicca syndrome. Initial awareness and a better understanding of RA in sub-Saharan Africa are necessary for the early management of these patients.

REFERENCES
1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010; 376(9746): 1094–1108.
2. Roux H. Polyrheumite rhumatoïde en Afrique subsaharienne. Rev Rhum. 2002; 69(8): 797–800.
3. Anaya JM, Correa PA, Mantilla RD, Jimenez F, Kuffner T, McNicholl JM. Rheumatoid arthritis in African Colombians from Quibdo. Semin Arthritis Rheum. 2001; 31(3): 191–198.
4. Ndongo S, Lekpa FK, Ka MM, Ndiaye N, Diop TM. Presentation and severity of rheumatoid arthritis at diagnosis in Senegal. Rheumatology (Oxford). 2009; 48(9): 1111–1113.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3): 315–324.
6. Malemba JJ, Mbuyi-Musamba JM, Mukaya J, Bossuyt X, Verschueren P, Westhovens R. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—a population-based study. Rheumatology (Oxford). 2012; 51(9): 1644–1647.
7. Pistor OM, Fantino B, Piot-Fantino G, Garret C, Trape G, Tehib I. [Diagnostic et prise en charge thérapeutique de la polyarthrite rhumatoïde en Rhône-Alpes: une enquête « vrai vie » en 2010.] Rev Rhum. 2013; 80(2): 130–135.
8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569–2581.
9. Korpella M, Lasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease modifying antirheumatic drugs: five year experience from the FIN-RACo study. Arthritis Rheum. 2004; 50(7): 2072–2081.
10. Tamhane A, McGwin G Jr, Redden DT, Hughes LB, Brown EE, Westfall AO, et al. Complementary and alternative medicine use in African Americans with rheumatoid arthritis. Arthritis Care Res. 2014; 66(2): 180–189.
11. Cornélie F. [Génétique de la polyarthritis rhumatoïde : un tournant décisif.] Rev Rhum. 2010; 77(4): 279–282.
12. Meyer O, Labarre C, Dougdos M, Goupille P, Cantagrel A, Dubois A. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five-year radiographic damage. Ann Rheum Dis. 2003; 62(2): 120–126.
13. Combe B, Dougdos M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J. et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 2001; 44(8): 1736–1743.
14. Ouédraogo DD, Singbo J, Diallo O, Sawadogo SA, Tièno H, Drabo YI. Rheumatoid arthritis in Burkina Faso: clinical and serological profiles. Clin Rheumatol. 2011; 30(12): 1617–1621.
الأعراض السريرية للتهاب المفاصل الروماتويدي في سكان جنوب الصحراء الأفريقية، دراسة 308 حالات من السنغال

صوهره وا تدونغو، وعبد الله يوي، وآدمير إيزنبان، ومورتالا مامادو كا، وتريسي موري ديبوب
قسم الطب الباطني، مستشفى أريستيد لي دانتيك العلمي
جامعة داكار، داكار - السنغال
قسم الطب الباطني، جامعة تيبيس، تيبيس - السنغال

المستخلص:

يُعتقد سابقا أن التهاب المفاصل الروماتويدي كان نادرا في جنوب الصحراء الكبرى الأفريقية، ولكنه الآن أصبح ينتشر على نحو متزايد. والهدف من هذه الدراسة هو تحديد الملامح السريرية والبيولوجية والبيوغرافية لالتهاب المفاصل الروماتويدي من أجل التشخيص والعلاج المبكر لهذا المرض.

وقد أجريت هذه الدراسة في قسم العيادات الخارجية للروماتيزم في مستشفى أريستيد لودانتك الجامعي في مدينة داكار في السنغال.

النتائج:

شملت هذه الدراسة ثلاثمائة وثمانية أشخاص من المصابين بالتهاب المفاصل الروماتويدي وفقا لمعايير 1987 للكلية الأمريكية لأمراض الروماتيزم، وهم 323 مريضا و 35 مريضة، وكانت نسبة النساء إلى الرجال 0.74، ومتوسط العمر 42 عامًا بين 21 و 52 عامًا. والقوة العمرية الشمالية 30-40 عامًا، يمكن أن يكون 93% في المناطق الحضرية، و 7% في المناطق الريفية، و هناك 31% من المرضى ظهر في عائلاتهم التهاب المفاصل، واستمرار 39% من المرضى معالجًا تقليديًا، و كانت نسبة إلحاء المفاصل الروماتويدي النشطة دوقة 81.4% والعامل الروماتويدي إيجابيًا في 94% من المرضى، كما أن الأطعمة المضادة للببتيدية متواجدة في 18% من المرضى تم إجراء الفحص عليهم، وقد ظهر على الأقل عرض واحد من أعراض المرض في نطاق المفاصل في 78% مريضا، وكانت أكثر الأعراض شيوعا فقر الدم ومتلازمة الجفاف.

الاستنتاج:

توصفت هذه الدراسة إلى أن إعلان المفاصل الروماتويدي يتم تشخيصه متأخرًا في مراحل مبكرة من المرض، وأنه يسبب عدة مفاصل وأن التحاليل المخبرية عالية الإيجابية، كما تميزت الإصابات خارج نطاق المفاصل بفقر الدم و متلازمة الجفاف. وخلصت هذه الدراسة إلى أن المعرفة الجيدة للالتهاب المفاصل الروماتويدي في جنوب الصحراء الكبرى من أفريقيا هو مطلوب ضروري للوصول إلى التشخيص والعلاج المبكر لهذا المرض.